Nektar Therapeutics Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Nektar Therapeutics (NKTR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 19.57 million shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2022-11-04
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-09-30 was 19.57M shares, a 11.01% increase year-over-year.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-06-30 was 20.54M shares, a 11.94% increase year-over-year.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-03-31 was 22.34M shares, a 15.19% increase year-over-year.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-09-30 was 17.63M shares, a 6.39% increase year-over-year.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for fiscal 2013 was 12.96M shares, a 7.24% decline from fiscal 2012.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for fiscal 2012 was 13.97M shares, a 34.50% decline from fiscal 2011.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for fiscal 2011 was 21.33M shares, a 10.35% increase from fiscal 2010.
- Nektar Therapeutics antidilutive securities excluded from computation of earnings per share, amount for fiscal 2010 was 19.33M shares, a 6.37% decline from fiscal 2009.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2022-09-30 | 19.57M shares 10-Q · filed 2022-11-04 | 20.81M shares 10-Q · filed 2022-11-04 | ||||
| 2022-06-30 | 20.54M shares 10-Q · filed 2022-08-05 | 21.43M shares 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | 22.34M shares 10-Q · filed 2022-05-06 | |||||
| 2021-09-30 | 17.63M shares 10-Q · filed 2022-11-04 | 18.45M shares 10-Q · filed 2022-11-04 | ||||
| 2021-06-30 | 18.35M shares 10-Q · filed 2022-08-05 | 18.87M shares 10-Q · filed 2022-08-05 | ||||
| 2021-03-31 | 19.39M shares 10-Q · filed 2022-05-06 | |||||
| 2020-09-30 | 16.57M shares 10-Q · filed 2021-11-05 | 17.50M shares 10-Q · filed 2021-11-05 | ||||
| 2020-06-30 | 17.11M shares 10-Q · filed 2021-08-06 | 17.97M shares 10-Q · filed 2021-08-06 | ||||
| 2020-03-31 | 18.82M shares 10-Q · filed 2021-05-07 | |||||
| 2019-09-30 | 17.16M shares 10-Q · filed 2020-11-06 | 18.01M shares 10-Q · filed 2020-11-06 | ||||
| 2018-09-30 | 17.60M shares 10-Q · filed 2019-11-07 | 3.20M shares 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | 3.20M shares 10-Q · filed 2019-08-09 | 3.10M shares 10-Q · filed 2019-08-09 | ||||
| 2013-12-31 | 12.96M shares 10-K · filed 2014-02-27 | |||||
| 2013-06-30 | 13.27M shares 10-Q · filed 2013-08-09 | 12.97M shares 10-Q · filed 2013-08-09 | ||||
| 2013-03-31 | 15.34M shares 10-Q · filed 2013-05-09 | |||||
| 2012-12-31 | 13.97M shares 10-K · filed 2014-02-27 | |||||
| 2012-09-30 | 14.30M shares 10-Q · filed 2012-11-09 | 13.84M shares 10-Q · filed 2012-11-09 | ||||
| 2012-06-30 | 24.12M shares 10-Q · filed 2013-08-09 | 23.57M shares 10-Q · filed 2013-08-09 | ||||
| 2012-03-31 | 23.89M shares 10-Q · filed 2013-05-09 | |||||
| 2011-12-31 | 21.33M shares 10-K · filed 2014-02-27 | |||||
| 2011-09-30 | 14.47M shares 10-Q · filed 2012-11-09 | 24.46M shares 10-Q · filed 2011-11-04 | 11.42M shares 10-Q · filed 2012-11-09 | 21.41M shares 10-Q · filed 2011-11-04 | ||
| 2011-06-30 | 21.61M shares 10-Q · filed 2012-08-09 | 21.30M shares 10-Q · filed 2012-08-09 | ||||
| 2011-03-31 | 21.12M shares 10-Q · filed 2012-05-04 | |||||
| 2010-12-31 | 19.33M shares 10-K · filed 2013-03-01 | |||||
| 2010-09-30 | 19.13M shares 10-Q · filed 2011-11-04 | 19.26M shares 10-Q · filed 2011-11-04 | ||||
| 2010-06-30 | 19.35M shares 10-Q · filed 2011-08-05 | 18.96M shares 10-Q · filed 2011-08-05 | ||||
| 2009-12-31 | 20.64M shares 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |